[HTML][HTML] Are epsins a therapeutic target for tumor angiogenesis?
N Klauber-DeMore - The Journal of clinical investigation, 2012 - Am Soc Clin Investig
N Klauber-DeMore
The Journal of clinical investigation, 2012•Am Soc Clin InvestigSolid tumor growth requires the formation of new blood vessels to supply nutrients and
oxygen to the malignant cells; one approach to cancer therapy is to block this process by
inhibiting VEGF signaling. In this issue of the JCI, Pasula et al. demonstrate a surprising role
of epsins—proteins involved in endocytosis—in tumor angiogenesis via their modulation of
VEGF signaling. Their findings suggest that these proteins might represent a new target for
the development of cancer therapeutics.
oxygen to the malignant cells; one approach to cancer therapy is to block this process by
inhibiting VEGF signaling. In this issue of the JCI, Pasula et al. demonstrate a surprising role
of epsins—proteins involved in endocytosis—in tumor angiogenesis via their modulation of
VEGF signaling. Their findings suggest that these proteins might represent a new target for
the development of cancer therapeutics.
Solid tumor growth requires the formation of new blood vessels to supply nutrients and oxygen to the malignant cells; one approach to cancer therapy is to block this process by inhibiting VEGF signaling. In this issue of the JCI, Pasula et al. demonstrate a surprising role of epsins — proteins involved in endocytosis — in tumor angiogenesis via their modulation of VEGF signaling. Their findings suggest that these proteins might represent a new target for the development of cancer therapeutics.
The Journal of Clinical Investigation